Molecular Mechanism for SHP2 in Promoting HER2-induced Signaling and Transformation

Abstract

The Src homology phosphotyrosyl phosphatase 2 (SHP2) plays a positive role in HER2-induced signaling and transformation, but its mechanism of action is poorly understood. Given the significance of HER2 in breast cancer, defining a mechanism for SHP2 in the HER2 signaling pathway is of paramount importance. In the current report we show that SHP2 positively modulates the Ras-extracellular signal-regulated kinase 1 and 2 and the phospoinositide-3-kinase-Akt pathways downstream of HER2 by increasing the half-life the activated form of Ras. This is accomplished by dephosphorylating an autophosphorylation site on HER2 that serves as a docking platform for the SH2 domains of the Ras GTPase-activating protein (RasGAP). The net effect is an increase in the intensity and duration of GTP-Ras levels with the overall impact of enhanced HER2 signaling and cell transformation. In conformity to these findings, the HER2 mutant that lacks the SHP2 target site exhibits an enhanced signaling and cell transformation potential. Therefore, SHP2 promotes HER2-induced signaling and transformation at least in part by dephosphorylating a negative regulatory autophosphorylation site. These results suggest that SHP2 might serve as a therapeutic target against breast cancer and other cancers characterized by HER2 overexpression.The Src homology phosphotyrosyl phosphatase 2 (SHP2) 2 functions as a positive effector of cell growth and survival (1-4), migration and invasion (5-8), and morphogenesis and transformation (9 -11). In receptor-tyrosine kinase signaling (12-14), SHP2 positively transduces the Ras-extracellular signal-regulated kinase 1 and 2 (ERK1/2) and the phosphoinositide-3-kinase-Akt (or protein kinase B) signaling pathways. SHP2 also promotes cell transformation induced by the constitutively active form of fibroblast growth factor receptor 3 and v-Src (9, 11). The discovery of germline-activating SHP2 mutations in Noonan and LEOPARD syndrome patients (15-18) and the subsequent experimental demonstration of these phenotypes in knockin and transgenic mice expressing these mutants (19,20) has led to the conclusion that disregulation of SHP2 is responsible for these disease states. Furthermore, somatic activating SHP2 mutations were discovered in juvenile myelomonocytic leukemia, acute myelogenous leukemia, and chronic myelomonocytic (18,21) and are suggested to play a causative role.SHP2 possesses two Src homology 2 (SH2) domains in the N-terminal region that allow the protein to localize to substrate microdomains after tyrosyl phosphorylation of interacting proteins. The phosphotyrosyl phosphatase (PTP) domain in the C-terminal region is responsible for dephosphorylation of target substrates (13,22). Mutation of the critical Cys residue in the active site of SHP2 abolishes its phosphatase activity, leading to the production of a dominant-negative protein (23). The activity of SHP2 is regulated by an intramolecular conformational switch. SHP2 assumes a "closed conformation" when inactive and an "open conformation" when active. In t...

Protein kinase Cδ is required for ErbB2-driven mammary gland tumorigenesis and negatively correlates with prognosis in human breast cancer

“…In cells depleted of PKCδ (shδ193 and shδ203), ligand-induced autophosphorylation of ErbB2 Y1221/1222 and Y1248 was slightly reduced, while phosphorylation of ErbB2 at Y877 was more dramatically reduced (Figure 4A and 4B, graphs) (40). Of note, total ErbB2 receptor protein was decreased in the absence of ErbB2 dimerization in shSCR cells, consistent with the findings that ErbB2 activation can decrease receptor turnover and stability (41–43). …”

The Tyrosine Phosphatase SHP2: A Key Molecule Linked both Type 2 Diabetes and Cancers?

“…Genetic and biochemical studies in recent years have suggested that SHP2 plays a broad role not only in cell proliferation [12], survival [13], and differentiation [14], but also in development [15,16] and tumorigenesis [17][18][19] of malignancies via Ras/Erk [20], PI3K/Akt [21] and other signaling pathways. In accordance to a recent study [18], our previous studies [22][23][24] have demonstrated that SHP2 plays a crucial role in breast oncogenesis. Recently, we have also found for the first time that SHP2 is widely expressed by lung cancer cells, and that the high expression of SHP2 may promote the invasion and metastasis of NSCLC through angiogenesis and the lymphatic system [25,26].…”

Multivariate signaling regulation by SHP2 differentially controls proliferation and therapeutic response in glioma cells

“…S4D), suggesting that EGFRvIII and c-MET are substrates of SHP2. These specific interactions have not been reported previously, but it has been reported that SHP2 can directly dephosphorylate other receptors, including HER2 (Zhou and Agazie, 2009), based on experiments using SHP2 DM .…”